NATICK, Mass., April 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that it has increased the interest rate payable on its $400 million 5.50 percent senior notes due November 15, 2015 ("2015 Notes") and its $350 million 6.25 percent senior notes due November 15, 2035 ("2035 Notes") each by 0.75 percent. The interest rate increase will accrue from November 17, 2005. The Company elected to adjust the interest rates due to the closing of the Company's acquisition of Guidant Corporation.

Pursuant to supplemental indentures entered into between the Company and J.P. Morgan Trust Company, National Association, Trustee for the 2015 Notes and the 2035 Notes, subsequent upgrades to the Company's long-term senior, unsecured debt credit ratings may result in a decrease in the interest rate of the 2015 Notes and the 2035 Notes, but in no event will the interest rate payable on the 2015 Notes be adjusted below 5.50 percent or the 2035 Notes be adjusted below 6.25 percent.

Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

Forward.Looking Statements

This press release contains forward-looking statements, including statements as to timing expectations to complete the merger and other statements identified by words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "projects", "plans", "will" and similar expressions intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risk factors relating to our industry as detailed from time to time in each of Boston Scientific's and Guidant's reports filed with the Securities and Exchange Commission, including each such company's most recent Annual Report on Form 10-K. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Boston Scientific undertakes no obligation to update publicly any forward-looking statements herein, whether as a result of new information, future events or otherwise.

  CONTACT:   Milan Kofol
             508-650-8569
             Investor Relations
             Boston Scientific Corporation

             Paul Donovan
             508-650-8541
             Media Relations
             Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Paul
Donovan, Media Relations, +1-508-650-8541 both of Boston Scientific
Corporation

Web site: http://www.bostonscientific.com/